放射配体治疗市场报告：趋势、预测和竞争分析（至 2030 年）

放射配体治疗的趋势和预测

全球放射配体治疗市场未来性，医院/诊所和诊断中心市场充满机会。预计到 2030 年，全球放射配体治疗市场将达到约 138 亿美元，2024 年至 2030 年的复合年增长率为 5.0%。该市场的主要驱动因素是癌症发病率的上升和对有效治疗的高需求。

• 在同位素类别中，Lucintel 预计，由于癌症诊断的高需求，氟 18 在预测期内仍将是最大的部分。
• 在最终用途类别中，由于久坐生活方式的盛行和全球癌症患者数量的不断增加，医院仍然是最大的部分。
• 从地区来看，由于专门的癌症医院和研究中心的存在以及全部区域的癌症发病率上升，预计北美在预测期内仍将是最大的地区。

放射配体治疗市场的策略性成长机会

由于技术进步和癌症治疗中标标靶治疗的接受度不断提高，放射配体治疗市场提供了各种机会。利用这些机会将带来业务进步和市场扩张。

• 前列腺癌治疗：由于前列腺癌的发生率不断上升，Pluvicto 等标靶治疗疗法继续受到欢迎。我们在这一领域的研发活动和业务的进一步扩展提供了巨大的成长机会，同时满足了对更有效治疗的需求。
• 神经内分泌肿瘤：由于监管和市场开拓的成功，神经内分泌肿瘤放射性配体治疗的预后诊断方法已被证明能够进一步开发和商业化。这个机会透过扩大目标人群来缩小公司的收益差距。
• 联合治疗：将放射配体治疗与免疫治疗和化疗结合可以使治疗更有效、更持久，并且可以避免抗药性。这为研究和市场成长提供了新的机会，使患者和治疗方法都受益。
• 新兴市场：潜在市场中放射性配体疗法的出现是为了满足对先进药物疗法不断增长的需求。这一机会将有助于扩大全球市场规模并提供接触新病患小组的机会。
• 先进影像的整合：透过整合PET、SPECT等先进成像技术，放射配体治疗在治疗精度和控制方面可以显着提高。这一机会透过提供更好的治疗选择来促进市场成长。

前列腺癌、神经内分泌肿瘤、联合治疗、新兴市场和先进的影像整合具有策略性的市场成长机会，可以利用这些机会来促进市场成长。这些机会推动了放射配体治疗市场的潜在扩张和技术进步。

放射配体治疗市场的驱动因素与挑战

放射配体治疗市场指南由多个监管、技术和经济驱动因素和挑战决定。解决这些因素对于市场成长和创新至关重要。

放射配体治疗市场的驱动因素

• 技术进步：随着新技术的发展，放射配体治疗变得更加有效和准确。新製造流程和先进成像技术的发现将透过提高治疗效果和扩大放射性配体治疗范围来促进市场成长。
• 癌症诊断的增加：癌症发生率的增加增加了对标靶治疗的需求。癌症发生率的增加将加速先进放射性配体疗法的商业化，并支持进一步的研究和开发，以满足未满足的医疗需求。
• 某些药物的监管核准：加速新治疗方法的监管核准简化了新放射性配体疗法的开发和引入。这个过程透过促进治疗开发的理想结果来促进市场成长。
• 增加研发投资：放射配体治疗的进步是由公司许多合作的努力所推动的。这种合作加强了研究和开发，带来新的提案和更有效的治疗方法。
• 发展更有针对性的癌症治疗方法：个人化医疗的发展使得针对个别患者的放射性配体疗法的开发成为可能。这可以透过满足特定患者的需求来改善治疗效果并扩大市场。

放射配体治疗市场挑战

• 开发成本高：开发新的治疗方法和技术可能成本高并阻碍进展。成本管理和投资规划对于企业保持竞争力至关重要。
• 监理障碍：遵守药品法规既困难又耗时。公司需要随时了解不断变化的法规，以加快新治疗方法的核准流程。
• 市场竞争：市场竞争会影响市场占有率和利润。公司必须创新以保持竞争力，提供强有力的临床证据，并与伙伴关係提高其市场地位。

放射配体治疗市场受到技术进步、癌症发生率增加、监管核准、研发投资以及个人化医疗趋势的推动。然而，为了确保成长和创新，必须解决高昂的开发成本、监管障碍和市场竞争。

目录

第一章执行摘要

第二章全球放射配体治疗市场：市场动态

• 简介、背景、分类
• 供应链
• 产业驱动因素与挑战

第三章 市场趋势及预测分析（2018-2030）

• 宏观经济趋势（2018-2023）与预测（2024-2030）
• 全球放射配体治疗市场趋势（2018-2023）与预测（2024-2030）
• 全球放射配体治疗市场：依同位素
  • 氟18
  • 镓68
  • 镏-177
  • 其他的
• 全球放射配体治疗市场：按目标受体
  • 摄护腺特异性膜抗原
  • 生长抑制素受体
  • 表皮生长因子受体
  • 其他的
• 全球放射配体治疗市场：依适应症分类
  • 摄护腺癌
  • 神经内分泌肿瘤
  • 乳癌
  • 其他的
• 全球放射配体治疗市场：依最终用途分类
  • 医院/诊所
  • 诊断中心
  • 其他的

第四章 各地区市场趋势及预测分析（2018-2030）

• 全球放射配体治疗市场：按地区
• 北美放射配体治疗市场
• 欧洲放射配体治疗市场
• 亚太地区放射配体治疗市场
• 其他地区放射配体治疗市场

第五章 竞争分析

• 产品系列分析
• 营运整合
• 波特五力分析

第六章 成长机会与策略分析

• 成长机会分析
  • 全球放射配体治疗市场成长机会：依同位素
  • 全球放射配体治疗市场成长机会：按目标受体
  • 全球放射配体治疗市场成长机会：依迹象分类
  • 全球放射配体治疗市场成长机会：依最终用途分类
  • 全球放射配体治疗市场成长机会：按地区
• 全球放射配体治疗市场的新兴趋势
• 战略分析
  • 新产品开发
  • 扩大全球放射配体治疗市场的产能
  • 全球放射配体治疗市场的企业合併
  • 认证和许可

第七章主要企业简介

• Novartis
• POINT Biopharma Global
• Molecular Partners
• Telix Pharmaceuticals
• Fusion Pharma
• Lantheus Holdings
• Curium
• Precrix
• Orano
• Artios Pharma

Radioligand Therapy Trends and Forecast

The future of the global radioligand therapy market looks promising with opportunities in the hospitals & clinics and diagnostic center markets. The global radioligand therapy market is expected to reach an estimated $13.8 billion by 2030 with a CAGR of 5.0% from 2024 to 2030. The major drivers for this market are rising cancer rates and the high demand for effective treatment.

• Lucintel forecasts that, within the isotope category, fluorine-18 will remain the largest segment over the forecast period due to the high demand for cancer diagnosis.
• Within this end-use category, hospitals will remain the largest segment due to the increasing prevalence of a sedentary lifestyle and the growing cases of cancer globally.
• In terms of regions, North America will remain the largest region over the forecast period due to the presence of specialized cancer hospitals and research centers, as well as the rising incidences of cancer across the region.

Gain valuable insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the Radioligand Therapy Market

The radioligand therapy market underscores the changes brought about by technology, clinical development, and patient treatment. These trends are transforming the landscape of chemotherapy and broadening the range of indications for radioligand therapies.

• Increased Focus on Personalized Medicine: Tailoring the pharmacological agents used in radioligand therapy to the patient's tumor markers and genetic makeup adds another dimension to the personalized medicine aspect of radioligand therapy. This also leads to better responses and fewer side effects, which promote the use of personalized therapies, thereby increasing the market potential for such therapies.
• Progress in Radiopharmaceutical Manufacturing: Increases in automation and better radiolabeling technologies make these production processes more efficient and amenable to scaling up, increasing the availability of radioligand therapies for patients. Such advancements meet the increasing market need for quality radiopharmaceuticals and simplify treatment procedures.
• Increase in Clinical Trials and Research: The expansion of clinical trials enhances the discovery of new treatments with radioligands as well as new markets for older drugs. Innovations and contributions toward radioligand therapy, anchored in evidence-based research, increase penetration and acceptance of the therapy in the market and among the population at large.
• Use of Other Imaging Approaches: Advanced imaging techniques, such as combining SPECT or PET with radioligands, enable researchers to monitor responses and locate cancer sites in real-time during the course of therapy, enhancing the accuracy of radioligand therapies. This trend improves patient management and outcomes as it increases treatment accuracy and, therefore, efficacy.
• Improvement in International Networking and Cooperation: With the central goal of optimizing research and clinical development of radioligand therapies, global partnerships enhance the movement of knowledge, resources, and technologies. The benefits of these collaborations include access to know-how and creativity, which fosters market development and increases the availability of new therapies.

The emerging themes of personalized medicine, new frontiers in radiopharmaceutical production, clinical research expansion, incorporation with imaging, and international collaborations are game-changers in the radioligand therapy market. These trends stimulate development, increase efficacy, and elevate the feasibility of targeted cancer treatment options.

Recent Developments in the Radioligand Therapy Market

The recent developments in radioligand therapy, which also include commercialization activities, emphasize technological advancements, clinical application patterns, and marketing trends. These developments create avenues for new research and further descriptive development of radioligand therapy in the management of localized cancer.

• FDA Approvals of Novel Therapies: This will broaden the scope of available therapies for patients suffering from neuroendocrine tumors and prostate cancer. It also opens up new market avenues and facilitates the innovation process in radioligand therapy by increasing the types of treatments available.
• Development of New Procedures for the Production of Radiopharmaceuticals: Advances in production technology contribute to the optimal utilization and bulk production of radiopharmaceuticals. These improvements benefit the expansion of the market, where the demand for higher-quality radioligand therapies continues to grow.
• Broadening of Clinical Trials: Expanding the scope of clinical trials accelerates the formulation of medicines and substantiates the claims made about current medications. This development enables further market growth through research and improvement of therapy modalities.
• Inclusion of Improved Imaging Techniques: The use of advanced imaging techniques adds to the accuracy and effectiveness of radioligand therapies. In this development, treatment response and tumor localization during treatment are monitored, improving patient management and outcomes.
• Collaborations and Partnerships Around the Globe: Partnerships help pool skills and assets, which in turn accelerate the development and marketing of radioligand therapies. These collaborations consolidate the global market and encourage creativity by working together.

In the last one and a half years, advances in FDA approvals, production, clinical trials, incorporation of imaging, and international collaborations have greatly influenced the radioligand therapy market. These advancements foster innovation, improve treatment effectiveness, and increase the potential for commercialization of products, thus defining future targeted cancer therapies.

Strategic Growth Opportunities for Radioligand Therapy Market

The radioligand therapy market presents various opportunities due to technological advancements and the growing acceptance of targeted therapy for cancer treatment. Taking advantage of these opportunities will help in business advancement and market expansion.

• Prostate Cancer Treatment: Targeted treatments like Pluvicto continue to gain traction due to the increasing incidence rates of prostate cancer. Further expansion of R&D activities and a larger footprint in this area present significant growth opportunities while addressing the need for more effective treatments.
• Neuroendocrine Tumors: Successful regulation and market access demonstrate that theragnostic approaches for radioligand therapy in neuroendocrine tumors can be further developed and marketed. This opportunity fills revenue gaps for businesses by expanding target populations.
• Combination Therapies: Combining radioligand therapies with immunotherapy or chemotherapy could make treatment more effective and lasting while avoiding resistance. This offers new opportunities for research and market growth, benefiting both patients and their treatments.
• Emerging Markets: The emergence of radioligand therapies in latent markets meets the increasing demand for advanced medication. This opportunity helps expand the size of the global market and provides access to new patient groups.
• Advanced Imaging Integration: Radioligand therapies are significantly improved in terms of treatment accuracy and management by incorporating advanced imaging techniques, such as PET and SPECT. This opportunity achieves market growth by providing better treatment options.

There are strategic market growth opportunities in prostate cancer, neuroendocrine tumors, combination therapies, emerging markets, and advanced imaging integration that can be exploited for market growth. These opportunities encourage potential expansion and technology enhancement in the radioligand therapy market.

Radioligand Therapy Market Driver and Challenges

The guiding factors for the radioligand therapy market are defined by several regulatory, technological, and economic drivers and challenges. Addressing these factors is essential for growth and innovation in the marketplace.

Drivers of the Radioligand Therapy Market:

• Technological Advancements: As new techniques are developed, radioligand therapies become more efficient and accurate. The discovery of new production processes and advanced imaging techniques improves treatment efficacy and contributes to market growth by broadening the scope of radioligand therapies.
• Increasing Cancer Diagnoses: The rising prevalence of cancer enhances the demand for targeted therapies. The growing incidence of cancer accelerates the commercialization of advanced radioligand therapies and supports further research and development to meet unmet medical needs.
• Regulatory Approvals for Certain Drugs: Faster regulatory approvals for new therapies help streamline the development and introduction of new radioligand treatments. This process fosters market growth by promoting the desired outcomes in treatment development.
• Increased Investment in R&D: Many collaborative efforts by companies have contributed to advancements in radioligand therapy. These collaborations enhance research and development, leading to proposed new applications and more efficient treatments.
• Development of More Targeted Treatments for Cancer: The movement toward personalized medicine is enabling the development of radioligand therapies for individual patients. This improves treatment outcomes and helps expand the market by meeting the specific needs of patients.

Challenges in the Radioligand Therapy Market:

• High Development Costs: The high costs associated with developing new therapies and technologies may hinder progress. Cost control and investment planning are essential for companies to stay competitive.
• Regulatory Roadblocks: Navigating regulatory requirements can be challenging and time-consuming. Companies must stay updated on evolving regulations to expedite approval processes for new therapies.
• Market Competition: Competition in the market may impact market share and profits. Companies must innovate and provide strong clinical evidence to stay ahead of the competition and engage in partnerships that enhance their market position.

The radioligand therapy market is driven by technological advancements, increasing cancer prevalence, regulatory approvals, R&D investment, and trends toward personalized medicine. However, high development costs, regulatory hurdles, and market competition must be addressed to ensure growth and innovation.

List of Radioligand Therapy Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies radioligand therapy companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the radioligand therapy companies profiled in this report include-

• Novartis
• POINT Biopharma Global
• Molecular Partners
• Telix Pharmaceuticals
• Fusion Pharma
• Lantheus Holdings
• Curium
• Precrix
• Orano
• Artios Pharma

Radioligand Therapy by Segment

The study includes a forecast for the global radioligand therapy by isotope, targeted receptor, indication, end use, and region.

Radioligand Therapy Market by Isotope [Analysis by Value from 2018 to 2030]:

• Fluorine - 18
• Gallium - 68
• Lutetium - 177
• Others

Radioligand Therapy Market by Targeted Receptor [Analysis by Value from 2018 to 2030]:

• Prostate-Specific Membrane Antigen
• Somatostatin Receptor
• Epidermal Growth Factor Receptor
• Others

Radioligand Therapy Market by Indication [Analysis by Value from 2018 to 2030]:

• Prostate Cancer
• Neuroendocrine Tumors
• Breast Cancer
• Others

Radioligand Therapy Market by End Use [Analysis by Value from 2018 to 2030]:

• Hospitals & Clinics
• Diagnostic Centers
• Others

Radioligand Therapy Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Radioligand Therapy Market

Recent developments in the radioligand therapy market include advances in technology, registration, and clinical practice. The growing trend among patients toward personalized medicine and targeted techniques is filling the gap created by recent activity in the field of radioligand therapies in countries like the United States, China, Germany, India, and Japan.

• United States: The US market for radioligand therapy is growing rapidly due to new FDA treatment approvals and the expansion of clinical trials. Recent developments include the release of promising drugs, such as Lutathera for treating neuroendocrine tumors and Pluvicto for treating prostate cancer. There is also a focus on improving technologies for radiopharmaceutical production and exploring new therapy combinations to improve treatment efficacy.
• China: China is making significant progress in radioligand treatment, focusing on building a local manufacturing base and expanding clinical trials. Recently, partnerships have been formed between Chinese pharmaceutical companies and international firms to develop new radioligand products. The country is also implementing regulatory schemes to facilitate approvals for radioligand therapies to meet the growing demand for tailored cancer treatments.
• Germany: Germany remains a leader in the radioligand therapy market, making continuous strides in research and development. German institutions are involved in clinical trials for new therapeutic radioligands targeting various cancers, including prostate and neuroendocrine tumors. The country is also enhancing its radiopharmaceutical manufacturing infrastructure and improving treatment control using advanced imaging techniques.
• India: The radioligand therapy market in India is evolving as the population becomes more engaged in oncology and personalized medicine. Clinical trials focusing on new radioligand therapies and global partnerships with research institutions have been established. The focus is on increasing the availability of new radiopharmaceuticals and expanding the use of existing ones to meet the growing patient pool.
• Japan: Japan is also progressing in the radioligand therapy market, with new treatment approvals and technological innovations. Japanese oncology organizations are developing new radioligand therapies and improving production technologies for both domestic use and export. The country is also increasing funding for research to find more indications and enhance existing treatments.

Features of the Global Radioligand Therapy Market

Market Size Estimates: Radioligand therapy market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Radioligand therapy market size by various segments, such as by isotope, targeted receptor, indication, end use, and region in terms of value ($B).

Regional Analysis: Radioligand therapy market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different isotope, targeted receptor, indications, end uses, and regions for the radioligand therapy market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the radioligand therapy market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the radioligand therapy market by isotope (fluorine - 18, gallium - 68, lutetium - 177, and others), targeted receptor (prostate-specific membrane antigen, somatostatin receptor, epidermal growth factor receptor, and others), indication (prostate cancer, neuroendocrine tumors, breast cancer, and others), end use (hospitals & clinics, diagnostic centers, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Radioligand Therapy Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Radioligand Therapy Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Radioligand Therapy Market by Isotope
  • 3.3.1: Fluorine - 18
  • 3.3.2: Gallium - 68
  • 3.3.3: Lutetium - 177
  • 3.3.4: Others
• 3.4: Global Radioligand Therapy Market by Targeted Receptor
  • 3.4.1: Prostate-specific Membrane Antigen
  • 3.4.2: Somatostatin Receptor
  • 3.4.3: Epidermal Growth Factor Receptor
  • 3.4.4: Others
• 3.5: Global Radioligand Therapy Market by Indication
  • 3.5.1: Prostate Cancer
  • 3.5.2: Neuroendocrine Tumors
  • 3.5.3: Breast Cancer
  • 3.5.4: Others
• 3.6: Global Radioligand Therapy Market by End Use
  • 3.6.1: Hospitals & Clinics
  • 3.6.2: Diagnostic Centers
  • 3.6.3: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Radioligand Therapy Market by Region
• 4.2: North American Radioligand Therapy Market
  • 4.2.1: North American Radioligand Therapy Market by Isotope: Fluorine - 18, Gallium - 68, Lutetium - 177, and Others
  • 4.2.2: North American Radioligand Therapy Market by End Use: Hospitals & Clinics, Diagnostic Centers, and Others
• 4.3: European Radioligand Therapy Market
  • 4.3.1: European Radioligand Therapy Market by Isotope: Fluorine - 18, Gallium - 68, Lutetium - 177, and Others
  • 4.3.2: European Radioligand Therapy Market by End Use: Hospitals & Clinics, Diagnostic Centers, and Others
• 4.4: APAC Radioligand Therapy Market
  • 4.4.1: APAC Radioligand Therapy Market by Isotope: Fluorine - 18, Gallium - 68, Lutetium - 177, and Others
  • 4.4.2: APAC Radioligand Therapy Market by End Use: Hospitals & Clinics, Diagnostic Centers, and Others
• 4.5: ROW Radioligand Therapy Market
  • 4.5.1: ROW Radioligand Therapy Market by Isotope: Fluorine - 18, Gallium - 68, Lutetium - 177, and Others
  • 4.5.2: ROW Radioligand Therapy Market by End Use: Hospitals & Clinics, Diagnostic Centers, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Radioligand Therapy Market by Isotope
  • 6.1.2: Growth Opportunities for the Global Radioligand Therapy Market by Targeted Receptor
  • 6.1.3: Growth Opportunities for the Global Radioligand Therapy Market by Indication
  • 6.1.4: Growth Opportunities for the Global Radioligand Therapy Market by End Use
  • 6.1.5: Growth Opportunities for the Global Radioligand Therapy Market by Region
• 6.2: Emerging Trends in the Global Radioligand Therapy Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Radioligand Therapy Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Radioligand Therapy Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Novartis
• 7.2: POINT Biopharma Global
• 7.3: Molecular Partners
• 7.4: Telix Pharmaceuticals
• 7.5: Fusion Pharma
• 7.6: Lantheus Holdings
• 7.7: Curium
• 7.8: Precrix
• 7.9: Orano
• 7.10: Artios Pharma